Merck Pays Up to $2.13 Billion for SciBrunch KRAS G12D Pill
Merck has licensed SPR2015, a preclinical oral KRAS G12D inhibitor, from SciBrunch Therapeutics in a global deal valued at $2.13 billion — another early-stage oncology bet as Keytruda's exclusivity window…
Merck & Co., Inc. (MRK) said Monday it has signed an exclusive global license agreement worth $2.13 billion with SciBrunch Therapeutics for SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor.
Merck & Co., Inc. (MRK) said Monday it has taken an exclusive global license to SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor, from SciBrunch Therapeutics under an agreement valued at $2.13 billion. The deal hands the American multinational pharmaceutical company worldwide rights to a compound that has not yet reached human testing — a reminder of how far upstream large-cap pharma is now willing to shop for oncology assets.
What Merck is actually buying
SPR2015 targets KRAS G12D, one of the most common cancer-driving mutations and, for decades, one of the least druggable. KRAS is a protein that acts as a molecular switch inside cells; when a single amino acid is swapped at position 12 — glycine to aspartic acid, hence G12D — the switch jams in the "on" position and tells the cell to keep dividing. That mutation is heavily represented in pancreatic cancer and turns up in colorectal and non-small cell lung tumors as well, patient populations where standard chemotherapy still defines the outlook.
The "(ON)" designation in the asset's description matters more than it looks. Early KRAS drugs worked by locking the protein in its inactive, or "off," state. An ON-state inhibitor binds the activated form directly, an approach the field has pursued because tumors carrying G12D spend more time in that active conformation. The other operative word is oral: a pill is cheaper to manufacture, easier to combine with other agents and far simpler to dose over long treatment courses than an infusion.
The qualifier that governs everything else here is preclinical. SPR2015 has no human safety data, no human efficacy data and no established dose. Merck is buying a scientific thesis and the option to test it, not a near-term product.
Why a $2.13 billion headline is not a $2.13 billion check
Biopharma licensing deals are almost always quoted at their maximum theoretical value, and readers should treat the $2.13 billion figure that way. The convention is an upfront payment, followed by a ladder of milestone payments tied to specific events — clearing investigational new drug filings, dosing a first patient, hitting a Phase 2 endpoint, winning regulatory approval in a given territory, and then crossing defined sales thresholds — plus royalties on eventual sales. The company disclosed the total deal value rather than a breakdown, so the split between cash at signing and contingent payments is not public from this announcement.
For a preclinical asset, the practical implication is that the overwhelming majority of that number is almost certainly conditional. Merck pays the later tranches only if SPR2015 keeps clearing hurdles, and the vast majority of preclinical oncology candidates do not. That structure is precisely why buyers are comfortable attaching billion-dollar headlines to molecules that have never been in a human being: the risk of failure sits largely with the seller's payout schedule, not the buyer's balance sheet. The terms were reported by Nasdaq Markets.
The pipeline math behind the shopping spree
Merck's strategic problem is well understood by anyone who follows the sector: its oncology franchise is heavily concentrated in a single immunotherapy, Keytruda, whose period of market exclusivity is finite. Every quarter that passes brings the loss-of-exclusivity cliff closer, and no single replacement asset is large enough to fill it. The response, across the industry and at Merck in particular, has been to buy breadth — a portfolio of shots on goal spanning mechanisms, tumor types and stages of development, in the expectation that a handful convert.
KRAS fits that logic neatly. It is a validated target class, which lowers the biological risk relative to a genuinely novel mechanism, and G12D specifically addresses tumor settings — pancreatic cancer above all — where the commercial opportunity is a direct function of how poorly existing options perform. An oral agent also slots into combination strategies with the immunotherapy and antibody-drug conjugate assets that large oncology portfolios are built around.
What SPR2015 cannot do is help in the near term. A preclinical compound needs to clear toxicology work, an IND filing and dose-escalation studies before it produces the kind of data that moves a revenue forecast. Investors treating this as a Keytruda answer are reading the wrong timescale; it is a bet on the back half of the decade and beyond.
Where the shares stood going in
The announcement came after the close of the prior week's trading. In the most recent session before the news, Merck last traded at 148.78, up 0.54% from a previous close of 147.98, with a day range of 147.48 to 149.98.
That move was in line with a broadly firm tape. The S&P 500 tracker (SPY) closed at $771.35, up 0.54%, against a previous close of $767.18. The Nasdaq 100 tracker (QQQ) finished at $744.50, a gain of 0.46%. The Dow tracker (DIA) was the strongest of the three at $517.49, up 0.94%. All figures are as of the last trade, 20:00 GMT on Friday, 25 September 2026; markets were closed at the time of writing.
Deals of this profile rarely move a company of Merck's size much on the day. The contingent structure means the immediate cash impact is modest, and the scientific payoff is years out. The share-price consequence, if there is one, tends to show up in how analysts describe the pipeline rather than in a single session's print.
What to watch from here
- Disclosure of the upfront payment. If Merck or SciBrunch breaks out the cash-at-signing component, that number is the cleanest read on how highly the buyer rates the preclinical data it has seen.
- The IND timeline. The first genuinely informative milestone is regulatory clearance to begin human trials. Until then, SPR2015 is a line item.
- Competitive positioning in G12D. Merck is not alone in chasing this mutation. Whichever ON-state oral inhibitor produces credible Phase 1 response data first sets the bar for everyone behind it.
- Further business development. One preclinical license does not constitute a strategy. The pattern worth tracking is whether Merck keeps adding early oncology assets at this pace and at these headline values.
- Combination intent. Any signal that SPR2015 is being positioned to pair with Merck's existing immuno-oncology backbone would indicate the company sees it as a portfolio anchor rather than a standalone option.
For now, the honest summary is narrow: a large pharmaceutical company has bought global rights to an unproven pill aimed at a hard target, and structured the price so that most of it is only owed if the science works. That is the standard shape of oncology dealmaking in 2026 — and the reason headline deal values deserve to be read with the word "up to" mentally inserted.
Key facts
- Deal value: $2.13 billion (total, including milestones)
- Asset: SPR2015, preclinical oral KRAS G12D (ON) inhibitor
- MRK last close: 148.78, +0.54%, as of 20:00 GMT Fri 25 Sep 2026
- Rights granted: Exclusive, global, licensed from SciBrunch Therapeutics
Frequently asked questions
What did Merck agree to with SciBrunch Therapeutics?
Merck & Co., Inc. announced on Monday that it entered an exclusive global license agreement with SciBrunch Therapeutics covering SPR2015, an investigational preclinical oral KRAS G12D (ON) inhibitor. The agreement is valued at $2.13 billion and gives Merck worldwide rights to develop and commercialize the compound. Merck is an American multinational pharmaceutical company.
Will Merck pay the full $2.13 billion?
Not necessarily. Biopharma license agreements are typically quoted at maximum potential value, combining an upfront payment with milestone payments that are only owed if the asset clears development, regulatory and sales thresholds. Merck disclosed the total figure but not the breakdown, so the share paid at signing is unknown from this announcement. Most of the value on a preclinical asset is usually contingent.
What is KRAS G12D and why does it matter?
KRAS is a protein that works as an on-off switch controlling cell growth. The G12D mutation swaps a single amino acid and jams that switch on, driving uncontrolled division. It appears frequently in pancreatic cancer and also in colorectal and lung tumors. KRAS was considered undruggable for decades, making any credible G12D inhibitor commercially significant.
What does 'preclinical' mean for the timeline?
Preclinical means SPR2015 has not yet been tested in humans. Before it can generate meaningful efficacy data, it must complete toxicology studies, clear an investigational new drug filing and progress through dose-escalation trials. That sequence typically takes years, so the asset cannot contribute to Merck's revenue in the near term regardless of how promising the science looks.
How does this relate to Keytruda's patent expiry?
Merck's oncology revenue is heavily concentrated in Keytruda, whose market exclusivity is finite. The company has responded by acquiring a broad set of early-stage oncology assets rather than seeking one replacement. SPR2015 fits that diversification strategy, but as a preclinical compound it addresses the back half of the decade, not the immediate exclusivity gap.
How did Merck shares trade around the announcement?
In the most recent session before the news, Merck last traded at 148.78, up 0.54% from a previous close of 147.98, within a day range of 147.48 to 149.98, as of 20:00 GMT on Friday, 25 September 2026. That was broadly in line with the market: the S&P 500 tracker closed at $771.35, also up 0.54%.
